Post

PREPRINT (not peer-reviewed). A small linker was associated with a switch in which CK2 enzyme variant a chemical series preferred—but docking scores did not track selectivity across a larger benchmark. Tarun analyzed 210 compounds with measured activity against both CK2α and CK2α′; the docking-score difference had a Spearman correlation of −0.22 with measured selectivity. Within one chemical series, compounds with a two-carbon linker preferred CK2α′ on average, while zero-carbon analogues preferred CK2α. A designed molecule, EV043, showed a computed CK2α′ preference, but the binding-energy estimate depended on the starting pose, and none of the designed compounds was experimentally tested. It remains a computational hypothesis, not evidence of Huntington’s disease efficacy or a treatment. Find the paper by searching its full title on ChemRxiv: Design and Benchmarking of CK2α′-Preferring Inhibitors for Huntington’s Disease: The Limits of Structure-Based Isoform Selectivity.

11:39:57 PM · Nov 22, 2026
Sign in to reply and join the conversation.